Drug Information

Drug General Information
Drug ID
D0P6DJ
Former ID
DNC005636
Drug Name
VATALANIB
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [521851], [541046]
Structure
Download
2D MOL

3D MOL
Formula
C20H15ClN4
InChI
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
InChIKey
YCOYDOIWSSHVCK-UHFFFAOYSA-N
CAS Number
CAS 212141-54-3
PubChem Compound ID
151194
PubChem Substance ID
8034494, 10318716, 11544568, 14827532, 46227754, 47207942, 50070546, 50071177, 50100112, 53790491, 57347324, 58107197, 77174846, 91616548, 92308747, 93619729, 93692965, 103317292, 103905548, 104171421, 104430401, 121264549, 125344798, 126652555, 126681092, 127342265, 127342266, 129776330, 131305145, 134339000, 134342841, 135141434, 136367735, 137001820, 142433490, 144206361, 152035902, 162187512, 162814431, 163790606, 164041949, 164235383, 164766095, 164830894, 165222126, 165238043, 165998596, 170466113, 172916394, 175426883
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 3 Target Info Inhibitor [527458]
Epidermal growth factor receptor Target Info Inhibitor [528774]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [528774]
mRNA of VEGFR1 Target Info Inhibitor [528016]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesionhsa04010:MAPK signaling pathway
ErbB signaling pathway
Calcium signaling pathway
HIF-1 signaling pathway
FoxO signaling pathway
Endocytosis
Dorso-ventral axis formation
Focal adhesion
Adherens junction
Gap junction
Regulation of actin cytoskeleton
GnRH signaling pathway
Estrogen signaling pathway
Oxytocin signaling pathway
Epithelial cell signaling in Helicobacter pylori infection
Hepatitis C
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Melanoma
Bladder cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
Choline metabolism in cancerhsa04014:Ras signaling pathway
VEGF signaling pathway
Proteoglycans in cancerhsa04014:Ras signaling pathway
Transcriptional misregulation in cancer
Rheumatoid arthritis
NetPath Pathway TNFalpha Signaling PathwayNetPath_16:IL4 Signaling Pathway
EGFR1 Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
EGF receptor signaling pathwayP00005:Angiogenesis
VEGF signaling pathway
Pathway Interaction Database VEGF and VEGFR signaling network
VEGFR3 signaling in lymphatic endotheliumlysophospholipid_pathway:LPA receptor mediated events
Signaling events mediated by PTP1B
Arf6 signaling events
Signaling events mediated by TCPTP
Thromboxane A2 receptor signaling
SHP2 signaling
Regulation of Telomerase
EGF receptor (ErbB1) signaling pathway
EGFR-dependent Endothelin signaling events
Posttranslational regulation of adherens junction stability and dissassembly
Direct p53 effectors
ErbB1 downstream signaling
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
E-cadherin signaling in keratinocytes
ErbB receptor signaling network
Internalization of ErbB1
Stabilization and expansion of the E-cadherin adherens junction
a6b1 and a6b4 Integrin signaling
Syndecan-3-mediated signaling eventshif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
S1P1 pathway
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network
HIF-2-alpha transcription factor network
S1P3 pathway
VEGFR1 specific signals
Reactome VEGF binds to VEGFR leading to receptor dimerizationR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
SHC1 events in ERBB2 signaling
PLCG1 events in ERBB2 signaling
PIP3 activates AKT signaling
GRB2 events in EGFR signaling
GAB1 signalosome
SHC1 events in EGFR signaling
EGFR downregulation
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
EGFR Transactivation by Gastrin
Constitutive Signaling by Aberrant PI3K in Cancer
Constitutive Signaling by EGFRvIII
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
WikiPathways Signaling by VEGFWP673:ErbB Signaling Pathway
Regulation of Actin Cytoskeleton
EGF/EGFR Signaling Pathway
MAPK Signaling Pathway
Focal Adhesion
Aryl Hydrocarbon Receptor Pathway
Extracellular vesicle-mediated signaling in recipient cells
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Bladder Cancer
Hair Follicle Development: Induction (Part 1 of 3)
Signaling by ERBB4
Signaling by ERBB2
Gastrin-CREB signalling pathway via PKC and MAPK
PIP3 activates AKT signaling
Nanoparticle-mediated activation of receptor signaling
Aryl Hydrocarbon Receptor
Spinal Cord Injury
Integrated Pancreatic Cancer Pathway
Gastric cancer network 2
AGE/RAGE pathway
Signaling Pathways in Glioblastoma
Arylhydrocarbon receptor (AhR) signaling pathway
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
Integrated Breast Cancer Pathway
Signaling by EGFR
L1CAM interactionsWP306:Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP306:Focal Adhesion
Angiogenesis
References
Ref 521851ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health.
Ref 541046(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705).
Ref 527458J Med Chem. 2005 Mar 10;48(5):1610-9.Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Ref 528016Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. Epub 2006 Feb 3.Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
Ref 528774Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. Epub 2007 Mar 23.Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.